ClinicalTrials.gg

Program

frexalimab

Also written as “Frexalimab”, “SAR441344 IV” and “SAR441344 SC”.

In Sanofi's pipeline, CD40L mAb. Its studies are mostly in Multiple Sclerosis · Glomerulosclerosis, Focal Segmental · Diabetes Mellitus, Type 1 · Lupus Erythematosus, Systemic · Sjogren's Syndrome, led by Sanofi.

Furthest: phase 3, since Nov 9, 202311 company-led studies, 9 open or runningNext primary completion: Dec 23, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi119 open or runningphase 3since Nov 9, 2023Sep 28, 2020Dec 23, 2026phase 2 · NCT06500702
  • Named in Sanofi’s own pipeline as frexalimab, phase 3, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2020First study: phase 2 study in Sjogren's SyndromeFirst studyNCT04572841 · 84 enrolled · United States, Argentina, Belgium and more
  2. May 6, 2021Phase 2 study in Multiple SclerosisNCT04879628 · 129 enrolled · United States, Bulgaria, Canada and more
  3. Sep 1, 2021Phase 2 study in Lupus Erythematosus, SystemicNCT05039840 · 109 enrolled · United States, Argentina, Brazil and more
  4. Apr 26, 2023Phase 1 study in Healthy VolunteersNCT05845996 · 56 enrolled · United States
  5. Oct 27, 2023Phase 2 study in Diabetes Mellitus, Type 1NCT06111586 · 197 enrolled · United States, Austria, Belgium and more
  6. Nov 9, 20232 phase 3 studies in Multiple SclerosisNCT06141486, NCT06141473
  7. Jul 8, 2024Phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702 · 84 planned · United States, Argentina, Australia and more
  8. Dec 23, 2025Phase 3 study in Multiple SclerosisNCT07325292 · 160 planned · United States, Belgium, Brazil and more
  9. Feb 3, 2026Phase 3 study in Kidney Transplant RejectionNCT07412470 · 526 planned · United States, Argentina, Australia and more
  10. Nov 3, 2026Phase 3 study in Multiple SclerosisNCT07930624 · 2,500 planned

Ahead

  1. Dec 23, 2026Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702
  2. Apr 28, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 1NCT06111586
  3. May 6, 2027Primary completion: phase 3 study in Multiple SclerosisNCT06141473
  4. Jul 15, 2027Primary completion: phase 3 study in Multiple SclerosisNCT07325292

TargetBeta

“CD40L mAb”the company's pipeline, read by Claude · source
“A Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2b Study With a Blinded Extension and an Optional Open-label Extension-Assessing the Safety and Efficacy of Frexalimab, a CD40L-antagonist Monoclonal Antibody, for the Preservation of Pancreatic β-cell Function in Adults and Adole…”study text, read by Claude · the study

Other programs on CD40LG

ProgramCompanyFurthest phaseStudies
dazodalibepruleAmgenphase 39
dapirolizumab pegolruleUCBphase 38
tegoprubartruleeledon-pharmaceuticalsphase 38
ravagalimabruleAbbViephase 24
OPT101ruleop-t-llcphase 24
TNX-1500ruleTonix Pharmaceuticalsphase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07930624Multiple Sclerosis3Not yet recruitingMay 16, 20312,500
NCT07412470Kidney Transplant Rejection · United States, Argentina, Australia and more3RecruitingAug 15, 2029526
NCT07325292Multiple Sclerosis · United States, Belgium, Brazil and more3RecruitingJul 15, 2027160
NCT06500702Glomerulosclerosis, Focal Segmental · United States, Argentina, Australia and more2RecruitingDec 23, 202684
NCT06141486Multiple Sclerosis · United States, Argentina, Australia and more3Active, not recruitingMar 24, 2028943
NCT06141473Multiple Sclerosis · United States, Argentina, Austria and more3Active, not recruitingMay 6, 20271,655
NCT06111586Diabetes Mellitus, Type 1 · United States, Austria, Belgium and more2Active, not recruitingApr 28, 2027197
NCT05845996Healthy Volunteers · United States1CompletedApr 10, 202056
NCT05039840Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more2Active, not recruitingSep 4, 2026109
NCT04879628Multiple Sclerosis · United States, Bulgaria, Canada and more2Active, not recruitingSep 21, 2022129
NCT04572841Sjogren's Syndrome · United States, Argentina, Belgium and more2CompletedNov 8, 202384

How it is read

Names in the registry

  • “Frexalimab”, 9 entries
  • “SAR441344 IV”, 2 entries
  • “SAR441344 SC”, 2 entries
  • “SAR441344”, 2 entries
  • “frexalimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.